These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15759362)

  • 1. Letrozole better than tamoxifen in postmenopausal women.
    Fricker J
    Lancet Oncol; 2005 Mar; 6(3):137. PubMed ID: 15759362
    [No Abstract]   [Full Text] [Related]  

  • 2. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    DeGrendele H
    Clin Breast Cancer; 2003 Dec; 4(5):311-2. PubMed ID: 14715105
    [No Abstract]   [Full Text] [Related]  

  • 4. Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
    Higa GM
    Drugs; 2006; 66(3):363-4. PubMed ID: 16526828
    [No Abstract]   [Full Text] [Related]  

  • 5. Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
    Oncology (Williston Park); 2005 Mar; 19(3):277, 360. PubMed ID: 15828547
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
    Scott LJ; Keam SJ
    Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
    Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN
    Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letrozole in breast cancer.
    Shahab N
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
    [No Abstract]   [Full Text] [Related]  

  • 12. Letrozole: advancing hormone therapy in breast cancer.
    Lee RJ; Armstrong AC; Wardley AM
    Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-operative endocrine therapy for postmenopausal women: when and why?
    Tondini C; Fenaroli P; Labianca R
    Ann Oncol; 2001 Nov; 12(11):1505-6. PubMed ID: 11822746
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
    Rossi E; Morabito A; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; De Maio E; Di Maio M; Piccirillo MC; De Feo G; D'Aiuto G; Botti G; Chiodini P; Gallo C; Perrone F; de Matteis A
    J Clin Oncol; 2009 Jul; 27(19):3192-7. PubMed ID: 19380451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letrozole as adjuvant therapy for postmenopausal women with early breast cancer.
    Russell CA
    Manag Care Interface; 2007 Sep; 20(9):30-1, 36. PubMed ID: 18161388
    [No Abstract]   [Full Text] [Related]  

  • 19. Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2011; 16(12):1762-70. PubMed ID: 22089970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior efficacy of letrozole versus tamoxifen as first-line therapy.
    Buzdar AU
    J Clin Oncol; 2002 Feb; 20(3):876-8. PubMed ID: 11821477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.